Exact Sciences Current Ratio 2006-2021 | EXAS

Current and historical current ratio for Exact Sciences (EXAS) from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Exact Sciences current ratio for the three months ending June 30, 2021 was 2.47.
Exact Sciences Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $1.67B $0.68B 2.47
2021-03-31 $1.78B $0.63B 2.82
2020-12-31 $2.20B $0.63B 3.47
2020-09-30 $1.61B $0.25B 6.36
2020-06-30 $1.51B $0.22B 6.77
2020-03-31 $1.48B $0.24B 6.09
2019-12-31 $0.55B $0.24B 2.34
2019-09-30 $1.32B $0.48B 2.75
2019-06-30 $1.38B $0.49B 2.79
2019-03-31 $1.41B $0.17B 8.39
2018-12-31 $1.23B $0.14B 9.02
2018-09-30 $1.29B $0.11B 12.08
2018-06-30 $1.31B $0.08B 15.79
2018-03-31 $1.12B $0.07B 15.30
2017-12-31 $0.49B $0.07B 7.15
2017-09-30 $0.51B $0.05B 10.34
2017-06-30 $0.53B $0.03B 16.81
2017-03-31 $0.31B $0.03B 10.23
2016-12-31 $0.33B $0.03B 10.87
2016-09-30 $0.36B $0.03B 11.94
2016-06-30 $0.25B $0.03B 8.71
2016-03-31 $0.28B $0.03B 11.51
2015-12-31 $0.33B $0.03B 12.19
2015-09-30 $0.36B $0.02B 15.28
2015-06-30 $0.22B $0.02B 11.92
2015-03-31 $0.26B $0.01B 17.69
2014-12-31 $0.29B $0.02B 16.65
2014-09-30 $0.22B $0.02B 12.91
2014-06-30 $0.24B $0.01B 24.32
2014-03-31 $0.12B $0.01B 13.16
2013-12-31 $0.14B $0.01B 17.47
2013-09-30 $0.15B $0.01B 17.50
2013-06-30 $0.16B $0.01B 19.81
2013-03-31 $0.10B $0.01B 10.54
2012-12-31 $0.11B $0.01B 9.49
2012-09-30 $0.12B $0.01B 12.47
2012-06-30 $0.07B $0.01B 8.48
2012-03-31 $0.09B $0.01B 11.11
2011-12-31 $0.09B $0.01B 11.83
2011-09-30 $0.08B $0.01B 10.33
2011-06-30 $0.08B $0.01B 11.90
2011-03-31 $0.09B $0.01B 14.13
2010-12-31 $0.10B $0.01B 13.36
2010-09-30 $0.04B $0.01B 4.67
2010-06-30 $0.04B $0.01B 5.06
2010-03-31 $0.02B $0.01B 3.17
2009-12-31 $0.03B $0.01B 3.88
2009-09-30 $0.03B $0.01B 3.72
2009-06-30 $0.03B $0.01B 3.84
2009-03-31 $0.02B $0.01B 2.94
2008-12-31 $0.01B $0.01B 1.02
2008-09-30 $0.01B $0.01B 1.04
2008-06-30 $0.01B $0.01B 1.55
2008-03-31 $0.01B $0.01B 1.90
2007-12-31 $0.01B $0.00B 2.92
2007-09-30 $0.02B $0.00B 3.92
2007-06-30 $0.02B $0.00B 4.99
2007-03-31 $0.02B $0.01B 3.05
2006-12-31 $0.02B $0.01B 3.37
2006-09-30 $0.03B $0.01B 4.09
2006-06-30 $0.03B $0.01B 4.47
2006-03-31 $0.03B $0.01B 5.19
2005-12-31 $0.03B $0.01B 5.42
2005-09-30 $0.04B $0.01B 6.32
2005-06-30 $0.04B $0.01B 6.93
2005-03-31 $0.05B $0.01B 7.85
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $16.160B $1.491B
EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76